Arterio-arterial graft – an option for hemodialysis patients with exhaustion of venous patrimony

Ana Castro1,2, Paulo Almeida3, Filipa Silva1, Duarte Rego3, Joana Tavares1, Josefa Santos1, Fernanda Silva1, José Alexandre Queirós1, António Cabrita1, Rui Almeida3

1 Serviço de Nefrologia, Centro Hospitalar do Porto, Porto, Portugal
2 Unit for Multidisciplinary Research in Biomedicine, Porto, Portugal
3 Serviço de Cirurgia Vascular, Centro Hospitalar do Porto, Porto, Portugal

ABSTRACT

Introduction: Vascular access (VA) for hemodialysis (HD) is the lifeline for End Stage Renal Disease (ESRD) patients. Long-term HD patients often have exhaustion of their venous patrimony for an autologous VA construction and, sometimes, even for a central venous catheter (CVC) placement.

Case report: We describe the case of a 43-year-old woman with ESRD due to lupus nephritis, on maintenance HD since 2009. She also had secondary antiphospholipid syndrome and was chronically anticoagulated. Nevertheless, the patient had multiorgan thrombotic events (without sequelae) and several episodes of irreversible thrombosis of arteriovenous fistulas. Her HD course was also marked by multiple severe CVC infections, at different locations; a hemoperitoneum during cholecystectomy, and an immediate thrombosis of the renal artery of a kidney transplant. She was admitted to our hospital after an irreversible dysfunction of a right jugular CVC, with documentation of thrombosis of the superior and inferior vena cava. Exhaustion of the venous patrimony for HD was assumed and it was decided to make an arterio-arterial graft (AAG) of early cannulation. The first cannulation of the AAG was performed two days after surgical intervention, with no complications. The patient performed a twelve hour per week HD treatment with good efficiency.

Conclusion: AAG is an alternative for HD patients who have exhausted all their venous patrimony and it can be considered prior to the placement of a CVC as their sole remaining vascular access.

Key Words: arterio-arterial graft; early cannulation graft; autologous vascular access; hemodialysis

INTRODUCTION

Worldwide, approximately 10% of the population has chronic kidney disease (CKD) and about 1.5 million require hemodialysis (HD)1.

The prevalence of ESRD patients requiring renal replacement therapy (RRT) is continuously increasing and is expected to reach 5.4 million worldwide by 20301. Most patients are treated with HD, which in most countries exceeds 60% of the prevalent ESRD population2.

Vascular access (VA) for hemodialysis is the lifeline for ESRD patients and arteriovenous fistula (AVF) is the preferred VA since it is associated with less complications. However, long-term HD patients often require multiple VA interventions. In Europe over 25% of all hospitalizations observed in ESRD patients are related with the construction and maintenance of a patent HD VA3.

When all the venous capital of an HD patient is exhausted, the use of an arterial access for HD may be
a viable option and, in fact, the use of an artery as a permanent VA is not a new procedure.

In this article we describe the clinical case of a patient with ESRD in HD treatment with venous capital exhaustion, including for central venous catheter (CVC) placement, for whom our team first arterial brachio-brachial graft of early cannulation was constructed.

**CASE REPORT**

We describe the case of a 43-year-old woman with ESRD due to lupus nephritis (LN) on maintenance HD since 2009. She was diagnosed with systemic lupus erythematosus (SLE) in 1993 when she was admitted at our hospital with a severe presentation of the disease, with cutaneous, haematological, hepatic, renal and pulmonary involvement. Immunosuppressive therapy with cyclophosphamide and corticosteroids was started with favorable clinical evolution. Posteriorly, she was also diagnosed with secondary antiphospholipid syndrome (APS) and despite the treatment with hypocoagulation she had several thrombotic events (cerebellar infarcts, pulmonary thromboembolism) without neurological deficits or other sequelae.

She evolved with progressive decline of renal function and severe arterial hypertension requiring the initiation of RRT by a tunneled CVC in the right internal jugular vein (RIJV) in February of 2008. Despite the close follow-up in our Vascular Access Consultation (VAC) and the multidisciplinary approach by Nephrology and Vascular Surgery, a complex path of vascular accesses followed (Fig.1). In 2008 a left brachiocephalic AVF was constructed, via which the patient began HD. However, she had a thrombosis without recovery in 2009 and this access was abandoned. This was followed by a complex course of multiple CVCs, with different locations and recurrent infectious complications. A new autologous VA (right brachiobasilic AVF) was constructed, but it also irreversibly thrombosed, and therefore, had to be abandoned. The total absence of venous patrimony compatible with the construction of an autologous VA in the upper limbs was confirmed after a new VAC evaluation.

In 2010 the patient had an acute lithiasic cholecystitis and underwent a laparoscopic cholecystectomy. Nevertheless, it was complicated with the hemoperitoneum requiring posterior laparotomy.

The patient was submitted to a deceased donor kidney transplant in 2011 with immediate thrombosis of the renal artery, and the kidney graft had to be removed.

In February of 2018 the patient had an infectious complication of the right femoral CVC (abscess of the tunnel that fistulized to the skin), and was referred by the HD center to our hospital to remove it and place a new one. Given the previous trajectory, it was decided to try to place, once again, an echo-guided and
A 19cm long-term catheter Cannon® II from Arrow with 15Fr was placed in the RIJV. Although the CVC progression was very difficult to perform, it was considered, at that point, the last feasible VA for the patient (Fig.2). A first HD treatment was performed at the hospital, with no complications.

After three HD treatments the CVC presented with irreversible dysfunction, probably due to its location. The patient was hospitalized for study and therapeutic orientation. Conservative therapy for CKD was immediately started and patient clinical and analytical surveillance was performed daily. The need for HD access was urgent.

A computed tomography angiography (CTA) of the thorax and abdomen was performed to characterize the entire vasculature, revealing that the CVC was introduced into the right internal jugular vein, the distal tip of which was in the most distal region of the superior vena cava (Fig.2). The entire upper vena cava had a thrombus around the catheter, without identification of the vessel wall or lumen. Upstream, the brachio-cephalic venous trunks were permeable. An important collateral circulation in the thoracic wall associated with the chronic superior vena cava thrombosis was seen. Surprisingly, it was also observed that the inferior vena cava was also completely obstructed, only permeable above the confluence of the suprahepatic veins.

Taking all these findings into account, we considered that the patient had exhaustion of the venous patrimony compatible with a vascular access for HD.

In this way, the clinical case was discussed with the Peritoneal Dialysis (PD) Unit to consider the possibility of performing PD. All the hospitalizations and surgical interventions related to the previous cholecystectomy, renal transplantation and all the intra-abdominal haemorrhagic/thrombotic complications that followed were carefully reviewed. It was concluded that after all episodes of intra-abdominal bleeding and laparotomies (with risk of associated adhesions), the technique had only a small chance of success.

After a multidisciplinary – Nephrology and Vascular Surgery – re-discussion of the patient, and considering the preservation of the thoracic arterial patrimony, the construction of an arterio-arterial graft (AAG) of early cannulation was proposed. A brachio-brachial (with end-to-end anastomosis) loop, using a 6 mm graft, was implanted in the left upper limb (Fig.3.1). At the end of the surgery the AAG pulse was present and the brachial pulse was also patent. No complications were reported.
Some particularities in the management of this type of graft were reviewed by the hemodialysis team: the puncture is in ladder, to prevent the creation of false aneurysms since there is very high venous pressure; it is not possible to perform hemodiafiltration since the inflow is made into the arterial circuit and would induce ischemia; the administration of drugs in the graft is contraindicated; more prolonged hemostasis time; Qb is limited by venous pressure, so in heavier patients an adequate dialysis dose will only be possible with 4 dialysis sessions or 3 long sessions.

The first cannulation was performed by an experienced HD nurse two days after the procedure (Fig. 3.2) using two 17G needles. The patient underwent a four-hour HD treatment without intercurrences. At the end a mean hemostasis time of approximately 30 minutes was observed. The patient was discharged to the hospital 1 week after surgery, during which dialysis therapy, namely ultrafiltration, was optimized. She maintained oral anticoagulation. Given the particular characteristics of the VA, the patient continued treatment in the HD unit of our hospital. She was treated with 12h of dialysis per week with mean Kt/V of 1.2, blood flow of 250-300 ml/min, an arterial pressure ranging from -70 to -50 mmHg and venous pressure ranging from 200 to 250 mmHg. Her height was 150 cm and dry weight was 44Kg, which permitted three treatments per week.

Two months after the procedure the patient was admitted with septic shock secondary to left lower limb cellulitis, and died in this context.

**DISCUSSION**

With the improved life expectancy of HD patients, we are confronted with patients who have exhausted their possible venous sites for AVF creation and arteriovenous graft (AVG) or even CVC placement.

In this article, the authors report the case of a young woman with APS, with multiple failure of autologous VA in the upper limbs due to thrombosis. In addition to the depletion of superficial and deep venous capital in the upper limbs, the construction of any access at this location was compromised due to occlusion of the superior and inferior vena cava. Although attempting to construct an AVF at the lower limb level was feasible, the likelihood of thrombosis was extremely high.

Whilst in 2010 the possibility of constructing this type of AV existed, the practices and access policy at that time were quite sparse and different from those currently implemented. Even for urgent situations, the response time was very long; at that time the only solution found was a CVC placement.

The sites available for catheter placement are finite and should be used sparingly. As we saw with this case, complications associated with long-dwelling catheters are frequent and inevitably lead to venous patrimony losses through time. In the femoral site we used the 50cm long-term catheter Cannon II from Arrow with 15Fr. However, since the patient had a severe infectious complication in her last right femoral CVC and a complete
obstruction of the inferior vena cava was observed, the possibility of a successful introduction of a new femoral CVC was excluded.

Although stenosis and thrombosis of central veins can be treated by angioplasty or surgically, these procedures require a suitable jugular vein or a patent contralateral venous outflow. Previous studies have demonstrated that treatment of central venous occlusions by angioplasty shows an excellent initial result, but 1-year primary patency rates are ≤ 50%; restenosis rates are high, and long-term results are uncertain. Given the severe AFS and all the previous thrombosis under anticoagulation, neither angiographic or surgical treatment of the central venous occlusions were performed. In order to preserve the venous entry site, the catheter exchange could be made through a guidewire, using, for example, a CVC with a reduced lumen CVC. However, in this case, given all the serious infectious complications, this possibility was not considered. We tried a recanalization, through a CVC placement, but it was not successful. It was possible to place the CVC in the right atrium by collaterality but the Qb was not adequate for HD.

In patients who have exhausted all possible conventional means for an autologous VA, an AAG can be the only other option for hemodialysis. In fact, the use of an artery as permanent vascular access for HD is not a new procedure.

The AAG was first described by Butt and Kountz in 1976. They reported good results with a femoropopliteal graft employed in seven patients in whom a conventional VA for HD was not possible. Since that time, a total of eight main retrospective studies were published between 1976 and 2017, reporting data of 151 patients. Primary patency rate ranged from 67%-94.5% at six months to 72%-87% at 36 months; secondary patency rates from 54%-61% at 36 months; drug administration is contraindicated in this form of vascular access. However, the most feared complication identified is distal ischemia associated with graft occlusion. Interestingly, in the studies performed the manifestations of ischemia were not concordant. In the published studies, the authors approached the anti-coagulation, the first needle puncture and the surveillance differently. In our patient we performed the first needle puncture 2 days after the AAG construction. She was already with anticoagulation. Unfortunately, in our case report the patient’s short follow-up period was the limiting factor in VA monitoring.

One of the main complications associated with the construction of AAG, given the arterial pressures, is the risk of development of false aneurysms. In this case, grafts with triple layer may confer an advantage. Thromboembolism or pharmacological embolism are also possible complications in AAG, so drug administration is contraindicated in this form of vascular access. However, the most feared complication identified is distal ischemia associated with graft occlusion. Interestingly, in the studies performed the manifestations of ischemia were not concordant. Nevertheless, Zanow et al noted that thrombosis of the femoral AAG required immediate thrombectomy. Thus, it may be reasonable to consider that in femoral AAG, thrombosis is associated with a more severe ischemia, so revascularization must be immediate. In the AAG of the upper limb, ischemia is more tolerable (probably due to collateral circulation), so revascularization may be delayed.

Our patient died of septic shock secondary to left lower limb cellulitis. Although the possibility of septic embolization could be considered, the AAG had no local infectious signs and there was an entrance door in the outer side of the left leg, making this the most probable starting point for the infection.
CONCLUSION

Although there is a lack of evidence on the use of AAG, the data obtained from the studies performed is encouraging. This is an alternative VA for HD patients who have exhausted all their definite access sites which can be considered prior to the placement of a CVC as their sole remaining VA. However, there is a need for a multicenter study with a larger population of patients.

Table 1

Postoperative management of arterioarterial grafts (adapted from 12)

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Anti-coagulation</th>
<th>First needle puncture</th>
<th>Surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khafagy et al13</td>
<td>Heparin 2500-3500 IU intra-op then warfarin post procedure. INR 1.5–2.5</td>
<td>If ePTFE, 2 weeks post-op, 48 hours postop if Flixene graft</td>
<td>Monthly clinical visits, and duplex every 3 months. Duplex assess for: (1) Patency; (2) Flow velocity; (3) Impending failing graft assessment. Every 3 months. (1) Graft blood flow mL/min (2) Urea reduction ratio % (3) Clinical exam (4) Duplex</td>
</tr>
<tr>
<td>Lei et al14</td>
<td>Heparin 4000 units once a day for 3–5 days and then aspirin 300 mg/day</td>
<td>Not before 2 weeks postop</td>
<td>–</td>
</tr>
<tr>
<td>Burger et al15</td>
<td>Heparin 3000 units once. Aspirin or clopidogrel or phenprocoumon from 3–5 days postop</td>
<td>Not before 2 weeks postop</td>
<td>Every 3 months</td>
</tr>
<tr>
<td>Moncef16</td>
<td>Heparin intra-op then warfarin. INR 2.5–3.0. If warfarin contra-indicated - aspirin 300 mg/day.</td>
<td>Day 1 postop</td>
<td>–</td>
</tr>
<tr>
<td>Zanow et al17</td>
<td>Heparin intra-op then warfarin. INR 2.5–3.0. If warfarin contra-indicated - aspirin 300 mg/day.</td>
<td>Not before 2 weeks postop</td>
<td>Every 6 months. (1) Graft blood flow mL/min (2) Urea reduction ratio % (3) Kt/V (4) Clinical exam (5) Duplex</td>
</tr>
<tr>
<td>Talaezadeh and Haghighi18</td>
<td>–</td>
<td>10 days</td>
<td>–</td>
</tr>
<tr>
<td>Giacchino et al19</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Butt and Kountz20</td>
<td>–</td>
<td>2 weeks</td>
<td>–</td>
</tr>
</tbody>
</table>

References


Correspondence to:
Ana Castro, MD
Serviço de Nefrologia, Centro Hospitalar do Porto
Largo Prof. Abel Salazar,4099-001 Porto, Portugal
E-mail: ana.coutinho.castro@gmail.com